Literature summary for 3.1.6.2 extracted from

Stanway, S.J.; Delavault, P.; Purohit, A.; Woo, L.W.; Thurieau, C.; Potter, B.V.; Reed, M.J.
Steroid sulfatase: a new target for the endocrine therapy of breast cancer (2007), Oncologist, 12, 370-374.

Search for more literature for 3.1.6.2

Application

Application	Comment	Organism
medicine	treatment of postmenopausal women with estrogen receptor-positie metastatic breast cancer using inhibitor 6-oxo-7,8,9,10,11,12-hexahydro-6H-cycloocta[c]chromen-3-yl sulfamate, i.e. STW64. Inhibitor almost completely blocks enzyme activity in peripheral blood lymphocytes and tumor tissues, inhibition is associated with significant reductions in serum concentrations of androstenediol and estrogens. Serum androstenedione concentration also decreases by up to 86%. Of eight patients that completed therapy, five show evidence of stable disease for up to 7 months	Homo sapiens

Inhibitors

Inhibitors	Comment	Organism	Structure
6-oxo-7,8,9,10,11,12-hexahydro-6H-cycloocta[c]chromen-3-yl sulfamate	i.e. STW64, treatment of postmenopausal women with estrogen receptor-positive metastatic breast cancer. Inhibitor almost completely blocks enzyme activity in peripheral blood lymphocytes and tumor tissues, inhibition is associated with significant reductions in serum concentrations of androstenediol and estrogens. Serum androstenedione concentration also decreases by up to 86%	Homo sapiens

Organism

Organism	UniProt	Comment	Textmining
Homo sapiens	-	patients with estrogen-receptor positive metastatic breast cancer	-

Source Tissue

Source Tissue	Comment	Organism	Textmining
breast cancer cell	-	Homo sapiens	-
lymphocyte	peripheral blood lymphocyte	Homo sapiens	-

Use of this online version of BRENDA is free under the CC BY 4.0 license. See terms of use for full details.

Release 2023.1 (January 2023)